• Recently visited:
Published on 2019-03-13 09:10:00 Share it web version
According to the medical intelligence data, the company's indapamide sustained-release tablets and the drug regulatory department issued the approval on January 14, 2016. Why didn't you see the company announcement? Both the 2017 annual report and the 2018 interim report said that the sustained release tablets are still being developed and have achieved initial results. Isn't the drug regulatory department issued a production license? Thank you
                                                    Lisheng Pharmaceutical:
Hello investors, the current indapamide sustained release tablets are still in the research and development stage. If there is any recent progress, the company will announce in time, thank you for your attention.
(from Interactive)                                                     Reply time 2019-03-15 08:03:00
Published on 2019-03-17 20:43:09
                                                “Shoubishan” brand 吲dapamine tablets is the main variety of the company. In the diuretic antihypertensive drugs, indapamide is one of the most effective drugs. The company is the first manufacturer to develop and produce indapamide products. It has always had an absolute advantage in the market share of indapamide. The market share is over 70%, ranking first in the country. According to statistics, in China, among the population aged 35 to 74, the incidence of hypertension is as high as 27%, the number of patients is close to 130 million, and more than 3 million are added each year. High blood pressure has now leapt to the top of the main cause of death! Is this introduction a fake?
Published on 2019-03-17 20:45:52
                                                The market share of sales is the first, and the market share is 70%. It is still in the process of research and development.
Comment on this topic
The post is gone! How to do?
Author: You will not be publishedlog in |5 seconds registration Author:, welcome to leave a messagedrop outPost a new topic
            Tip: All information, comments, etc. published by users in the community represent only personal opinions, and are not related to the position of this website, and do not constitute any investment advice for you. Users should make their own decisions on securities investment and bear the corresponding risks based on their own independent judgment."Review of Self-discipline Management Commitment"